As already demonstrated in CML, BMI1 is responsible for the resistance to the tyrosine kinase inhibitors (TKIs) in a BCR-ABL1-independent way. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.